Orthofix Medical Inc. (NASDAQ:OFIX) Receives $21.75 Consensus PT from Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $21.25.

Several equities analysts have weighed in on the company. Barrington Research reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Orthofix Medical in a report on Thursday, October 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a report on Wednesday, October 8th. Wall Street Zen upgraded Orthofix Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Stifel Nicolaus initiated coverage on Orthofix Medical in a research note on Tuesday. They issued a “buy” rating and a $22.00 price target on the stock.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $16.02 on Friday. The stock has a market capitalization of $632.63 million, a PE ratio of -5.05 and a beta of 0.89. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50. The business has a fifty day moving average price of $14.83 and a two-hundred day moving average price of $12.94. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $20.73.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.40). The company had revenue of $203.12 million during the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Orthofix Medical will post -2.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Orthofix Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC increased its stake in shares of Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 955 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in Orthofix Medical during the 3rd quarter worth $30,000. US Bancorp DE lifted its holdings in Orthofix Medical by 684.6% during the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company’s stock worth $93,000 after buying an additional 4,950 shares during the period. Strs Ohio acquired a new position in Orthofix Medical during the 1st quarter worth about $150,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Orthofix Medical during the 1st quarter worth about $164,000. Institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.